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Smarq Thirty-four evahuable patients were treated with vinorelbine, a novel, semisynthetic yica alkaloid,
as first-line chemotherapy for advanced breast cancer. They receved vinorebine 25 mg m2 i.v. given weekly
for a maximum of 16 cyces. Two patients achieved a complete remission and 15 a partial remission, giving a
response rate of 17/34 (501%; 95% CI of 34-66%); median response duration was 5.8 months. The median
progression-free interval was 4A months and median survival 9.9 months. Treatment was generally well
tolerated. Fatigue was the most common side-effect. The main reason for dose adjustments was myekosppres-
sion; 68% of patients had WHO grade 3 or 4 neutropenia and there was one death attributed to neutropenic
sepsis. Nausea/vomiting and neuropathy were mild and alopecia was uncommon. This study confirms
vinorelbine as a highly actve, well-toleated agent in advanced breast cancer worthy of evaluation in
combination chemotherapy regmens.
Although a wide range of agents are active against breast
cancer, the treatment of advanced disease is palliative not
curative. There remains a need for new agents with either
greater activity or reduced toxicity compared with those now
in use. The vinca alkaloids were first evaluated in breast
cancer during the 1960s. Response rates for vincristine and
vinblastine, and later the semisynthetic compound vindesine,
were modest and neuropathy significant (Henderson, 1991).
As a result, these agents have had only a limited role in the
treatment of advanced breast cancer. More recently a new
group of compounds, differing in both the vindoline and
catharanthine moeities, was synthesised, of which vinorelbine
(nor-5'-anhydrovinblastine, Navelbine) has entered clinical
trials (Figure 1).
Preclinical studies suggested that vinorelbine may have an
improved therapeutic index relative to other viyca alkaloids.
In common with other vinca alkaloids vinorelbine acts on the
mitotic spindle. However, the effect of vinorelbine on tubulin
differs qualitatively and quantitatively from that of vincris-
tine or vinblastine (Fellous et al., 1989). Inhibition of tubulin
polmerisation is greater, but induced spiralisation less, with
vinorelbine than with vinblastine. Vinorelbine has activity
against a wide range of murine tumours, including L1210
leukaemia, P388 leukaemia and B16 melanoma. It is also
effective against human lung and stomach xenografts (Cros et
al., 1989). In the phase I clinical study by Mathe and
Reizenstein (1985) neutropenia was the dose-limiting toxicity
in heavily pretreated patients. Neurotoxicity was mild,
although many patients had previously received other vinca
alkaloids. When the current study opened in 1992, pre-
liminary reports of phase II studies suggested that vinorel-
bine 30 mg m2 given weekly had substantial activity in
heavily pretreated patients (Marty et al., 1989) and as first-
line chemotherapy for advanced breast caner (Canobbio et
al., 1989; Fumoleau et al., 1990; Mickiewicz et al., 1991).
Prior to the current study vinorelbine had not been
evaluated in the UK. The aim of this phase II study was to
determine the efficacy and toxicity of vinorelbine 25 mg m-2
given weekly to patients with advanced breast cancer at
centres within this country. Previous studies evaluating a
dose of 30 mg m-2 had required frequent dose modifications
(Canobbio et al., 1989; Fumoleau et al., 1990; Mickiewicz et
al., 1991). A slightly lower dose was selected for the current
study in an attempt to maintain the planned dose intensity
without sacrificing efficacy.
Eties ad mtos
Patients
Eligible patients had histologically confirmed advanced breast
cancer with at least one bidimensionally measurable lesion.
They had not received prior chemotherapy for advanced
dises but previous adjuvant chemotherapy was permitted
provided there had been a 6 month disease-free period after
finishing such treatment. Prior endocrine treatment and
radiotherapy were allowed. Other eligibility criteria included:
CH2CH3
COOCH3
Compound RI R2
Vinorelbine - CH3
V\inblastine OH* CH3
Vincristine OH* CHO
WVinblastine and vincristine
have no double bond at Rl.
Figwe I Structure of the vinca alkaloids.
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WHO performance status 0-2; age 18-75 years; white blood
cells>3.0 x 10 1-'., neutrophils>2.0 x 1091` and plate-
lets> 100 x 1091-1; serum bilirubin, serm transaminases
and creatinine< 1.25 times the upper limit of the reference
range (unless the abnormalities were directly attributable to
breast cancer). Patients with clinical signs of peripheral
neuropathy (unless directly attributable to malignancy), brain
metastases or a previous history of other malignancy were
excluded.
Treatment toxicity was assessed according to WHO (1979)
criteria and response by UICC guidelines (Hayward et al.,
1981). Bone metastases were not accepted as the sole site of
evaluable disease. They were assessed only if lytic and were
then considered evaluable but not measurable. The protocol
specified a response rate of 20% as the lowest that may
indicate significant treatment efficacy. Response duration,
progression-free interval and survival were measured from
the date of the first cycle of vinorelbine (Kaplan & Meier,
1958).
All patients gave informed, written consent and the study
was approved by the ethics committee of each of the par-
ticipating hospitals.
Treatmentplan
Patients received vinorelbine as an intravenous bolus injec-
tion over 3-5 min followed by flushing with saline. Treat-
ment was given weekly, initially at a dose of 25 mg m-2. This
was reduced to 20 mg m2 if subsequently the neutrophils
were 1.0-1.5 x 109 1-' or platelets 75-100 x 1091-'. Treat-
ment was delayed if the blood count was lower than these
values. Patients who developed neurotoxicity of WHO grade
2 or worse had treatment delayed until this recovered. If
neurotoxicity persisted for more than 4 weeks treatment was
to be discontinued. Patients who responded could receive a
maximum of 16 weekly cycles of vinorelbine; those with
stable disease received a maximum of eight treatments. Most
patients routinely received metoclopramide 10 mg i.v. alone
as antiemetic cover. Treatment at relapse was at the dis-
cretion of the clinician.
Results
A total of 35 patients entered the study between April and
December 1992. One patient, who was ineligible since she
remained on tamoxifen, was excluded from the analyses. The
pretreatment characteristics of the remaining 34 eligible
patients, one of whom was male, are shown in Table I.
These patients received a total of 354 cycles of vinorelbine;
the median number of cycles administered was 10 (range
3-16). Nine patients completed the full course of 16 cycles of
vinorelbine and 13 stopped because of progressive disease. Of
the remaining patients, five declined further treatment and six
stopped at their physician's discretion (two with a partial
remission and four with stable disease); there was one toxic
death. The median dose-time treatment intensity was 79%
of that planned (range 55-99%). Dose adjustments were
made for 129 (36%) cycles of vinorelbine; 53 (15%) cycles
were given at a reduced dose, 61 (17%) were delayed and 15
(4%) were both delayed and given at reduced dose. Neutro-
penia accounted for most dose adjustments 98/129 (76%).
All 34 patients were evaluable for treatment efficacy and
toxicity with a median follow-up of 18.2 months. Two
patients achieved a complete response (CR), 15 a partial
response (PR), 12 stable disease and five had progressive
disease. The response rate was, therefore, 50% with 95%
confidence intervals (CI) of 34-66%; median response dura-
tion was 5.8 months (range 2.3-9.8 months). The male
patient did not respond to vinorelbine. As Table II shows,
responses were seen at each of the sites of disease. In all,
35 responses were seen from a total of 76 measurable or
evaluable disease sites (46%). The median time to progres-
sion for all 34 patients was 4.4 months (range 0.9 to > 14.4
Table I Characteristics of evaluable patients (n = 34)
Median age (years)
Sex
Female
Male
Median time from diagnosis to
vinorelbine (months)
ECOG performance status:
0
1
2
Histology
Infiltrating ductal
Infiltrating lobular
Other/unklnown
Receptor status:
ER positive
ER negative
Unknown
PR positive
PR negative
Unknown
Prior systemic treatment:
Adjuvant endocrine
Adjuvant chemotherapy
Advanced endocrine
Measurable/evaluable disease sites:a
Cutaneous
Lymphatic
Breastlocal recurrence
Soft tissue
Bone
Visceral
Other
59 (range 34-75)
33 (6 pre- and 27
post-menopausal)
l
24 (range 0-187)
13
16
5
21
5
8
9
0
25
7
2
25
18
3
19
11
22
9
4
7
18 (12 lung, six liver)
5 (three ascites, one
pleural, one abdominal)
'Eightpatientshadone, 13 patientshad twoand 13patientshadthree or
more sites ofmeasurable/evaluable disease
Table 11 Response to vinorelbine by disease site
Responses (%)
Disease site (n} CR PR CR + PR
Skin (11) 4 3 7 (64)
Lymph nodes (22) 6 5 11 (50)
Breast local recurrence (9) 1 2 3 (33)
Soft tissue (4) 1 2 3 (75)
Bone (7) 1 1 2 (29)
Visceral (18) 2 6 8 (44)
Other (5) 1 0 1 (20)
Total (76) 16 19 35 (46)
months); median survival was 9.9 months (range 1.8 to
>21.1 months).
Haematological toxicity is shown in Table III and other
WHO toxicities in Table IV. Neutropenia was the main
toxicity. WHO grade 3 or 4 neutropenia was experienced by
12 patients and 11 patients respectively; this occurred in 16%
of treatment cycles. There was one toxic death, attributed to
neutropenic sepsis, in a woman who died 5 days after her
12th cycle of vinorelbine. Contrary to the protocol this had
been given at full dose, rather than reduced to 20 mgm-2,
despite a neutrophil count of 1.3 x O11-'. This patient
received two previous cycles of treatment without the dose
modifications recommended in the protocol. Significant
anaemia was very uncommon, with only one patient develop-
ing WHO grade 3 toxicity for a single cycle of vinorelbine.
Thrombocytopenia was not observed.
Non-haematological toxicity was generally mild. Asthenia
(tiredness), which is not graded by WHO criteria, was the
most common symptom during treatment. Mild, moderate"2 CJ. TWELVES et al.
Table m Maximum haermatoogical toxicity
Number ofpatients Number ofcycles'
WHO grade WHO grade
Toxicity 0 1 2 3 4 0 1 2 3 4
Neutropenia 2 2 7 12 11 172 50 62 37 18
68% 16%
Leucopenia 0 5 11 16 2 130 85 84 41 3
53% 13%
Thrombocytopenia 34 0 0 0 0 343 0 0 0 0
0% 0%
Anaemia 9 18 6 1 0 190 129 23 1 0
3% <1%
an = 343 evaluable cycles, except for neutrophils, where n= 339 cycles.
Table IV Maximum non-haematological toxicity
Number ofpatients Number ofcycles
WHO grade WHO grade
Toxicity 0 1 2 3 4 0 1 2 3 4
Nausea/vomiting 10 12 8 4 0 240 79 22 4 0
11% 1%
Neuropathy 24 7 3 0 0 284 54 7 0 0
0% 0%
Alopecia 10 13 7 4 0 213 78 47 7 0
12% 2%
Constipation 11 10 11 2 0 269 47 26 3 0
6% <1%
Diarrhoea 24 4 5 1 0 322 15 7 1 0
3% <1%
Infection 17 13 2 1 1 320 22 2 1 1
6% <1%
Phlebitis 19 8 6 1 0 296 34 13 2 0
3% <1%
Stomatitis 20 10 4 0 0 311 28 6 0 0
0% <0%
an = evaluable 345 cycles, except for infection, where n = 346 cycles.
and severe asthenia were reported with 26%, 24% and 3.5%
respectively of cycles of vinorelbine; these degress of asthenia
were experienced by 29%, 26% and 6% patients respectively.
Table IV shows the other non-haematological WHO tox-
icities. Infection was uncommon and WHO grade 3 and 4
infection associated with only two cycles of treatment in two
patients, one of whom died. Peripheral neuropathy was
uncommon and mild; the worst neuropathy experienced was
grade II in three patients. Although the majority of patients
received metoclopramide as the only antiemetic, most cycles
ofchemotherapy were associated with no clinically significant
nausea and vomiting. Severe (WHO grade 3) vomiting was
recorded in 4% of patients, although this represented only
1% of treatment cycles. Alopecia was mild and stomatitis
was uncommon.
The preliminary results of several studies evaluating vinorel-
bine given as a single agent in patients with advanced breast
cancer have been reported (Marty et al., 1989; Canobbio et
al., 1989; Fumoleau et al., 1990; Mickiewicz et al., 1991;
Lluch et al., 1992). However, so far the final results of only
two studies have been published (Fumoleau et al., 1993;
Romero et al., 1994). It is valuable to evaluate a new agent
in different populations since treatment principles may differ
between countries. The most important finding of this phase
II study conducted at several centres in the UK is to confirm
that vinorelbine has considerable activity, and is well
tolerated, in patients with advanced breast cancer.
There are differences between the current study and the
previous published phase II trials in patients with advanced
breast cancer (Fumoleau et al., 1993; Romero et al., 1994).
Firstly, this is the first study to have evaluated the dose of
25 mgm2 rather than 30mgm2. Secondly, patients who
responded received a maximum of 16 cycles rather than
continuing to disease progression or dose-limiting toxicity as
was the case for both the other trials. The response rate of
50% in the current study was very similar to that of 41%
reported previously (Fumoleau et al.. 1993; Romero et al.,
1994). Median time to progression in all patients was 4.4VINORELBINE IN ADVANCED BREAST CANCER 993
months in the current study, only slightly less than the 6.0
months reported by Fumoleau et al. (1993) and Romero et
al. (1994). The median response duration in our study was
5.8 months. substantially shorter than that of 7.8 months and
9 months reported by both the earlier studies (Fumoleau et
al.. 1993: Romero et al.. 1994). Similarly, the median survival
of 9.7 months in the current study was substantially less than
that of 18 months reported previously (Fumoleau et al..
1993). These discrepancies may be the result of differences in
the patient populations. However, the pretreatment charac-
teristics of the patients were similar and the median number
of treatment cycles given and delivered dose-time intensity
were also similar. The longer response duration reported by
Fumoleau et al. (1993) and Romero et al. (1994) may reflect
the differing treatment policies whereby patients who res-
ponded continued treatment to progression or unacceptable
toxicity. A further difference may be better survival after
relapse following vinorelbine in the earlier trials (Fumoleau
et al.. 1993: Romero et al.. 1994). This might be explained by
differences in the treatment regimens, and their efficacy,
between the various study populations.
Vinorelbine was generally well tolerated in the current
study. The most consistent toxicity was asthenia or tiredness,
which may be drug related or a result of the underlying
cancer. Tiredness is not included in WHO toxicity scales and
was not assessed by Fumoleau et al. (1993) or Romero et al.
(1994). This emphasises the advantages of using the NCI
common toxicity criteria, which do evaluate tiredness, and of
including quality of life measures in phase III studies of
palliative chemotherapy. Myelosuppression, specifically neut-
ropenia, was the main WHO toxicity. This was responsible
for the overwhelming majority of dose adjustments. The
single toxic death may have resulted from a clinical decision
not to lower the dose to 20 mgm2' in a patient with a
neutrophil count of -1.3 x 09 1-' as this was only marginally
below the dose reduction level. Gastrointestinal toxicity and
peripheral neuropathy were mild, and alopecia was uncom-
mon. This pattern of toxicity in the current study was very
similar to that descnrbed previously (Fumoleau et al., 1993;
Romero et al., 1994).
Comparisons between the response rates with vinorelbine
and those of other vinca alkaloids are difficult since in the
early studies the patient groups were less well defined and
standard assessment cnrteria were often not available. Never-
theless, in a review by Henderson (1991) the response rates
quoted for vincristine 19% (CI 15-24%), vinblastine 21%
(CI 15-29%) and vindesine 24% (CI 18-30%) appear lower
than that for vinorelbine of 43% (95% CI 36-50%) in the
three phase II studies now published. The response rates to
vinorelbine are similar to those of the most effective single
agents in advanced breast cancer (Henderson, 1991). This
encouraging activity and low toxicity of vinorelbine given as
a single agent have led to studies investigating its activity in
combination with other agents as first-line treatment in
patients with advanced breast cancer. Preliminary results
have been encouraging. Dieras et al. (1990) reported a res-
ponse rate of 63% in patients receiving vinorelbine
30 mg m-2 with 5-fluorouracil 750 mg m-2 by continuous
infusion, each given on days 1 and 5 every 3 weeks. The
combination of vinorelbine 25 mg m-2 on days I and 8 with
doxorubicin 50 mg m-2 on day I achieved a response rate of
78% (Dorval et al., 1991).
This study has confirmed that vinorelbine 25 mgm' given
weekly as a single agent is highly active and well tolerated as
first-line treatment in patients with advanced breast cancer.
These encouraging phase II data need to be confirmed in
phase III studies supported by quality of life data. Vinorel-
bine may then have an important place in the treatment of
patients with advanced breast cancer, as adjuvant treatment
in women with early disease or primary chemotherapy for
locally advanced disease.
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